Thursday, September 3, 2015
The Oslo Cancer Cluster Innovation Park in Norway has opened. A $122.8 million, public-private investment, the Innovation Park brings together the research, healthcare and industry partners in the Oslo oncology value chain with the Ullern High School.
Over the past 10 years, the U.K. biotech sector has outperformed other European countries, raising $1.4 billion via IPOs and $2.4 billion in venture capital, according to a new report from life science market intelligence firm Evaluate and the U.K. BioIndustry Association (BIA). The rise in optimism has been most evident in 2014, with the momentum continuing into 2015.
The All Party Parliamentary Group (APPG) on Life Sciences has launched to raise awareness and understanding of the valuable contribution the life sciences sector provides to the health and the wealth of the U.K.
Public Health England will transfer its drug development and production to a new company, Porton Biopharma. The transfer of Public Health England’s (PHE’s) clinical drug development and production capability into a stand-alone, state-owned biopharmaceutical limited company has been approved by the Secretary of State for Health.
The EMA has granted Orphan Drug designation to a gene transfer therapeutic currently in clinical development in the U.S. for the treatment of type 1 spinal muscular atrophy (SMA). AveXis, a gene therapy company developing treatments for rare and life-threatening genetic diseases, received Orphan Drug designation for SMA in the U.S. in Oct. 2014.